web analytics
-0.8 C
Munich
Saturday, November 26, 2022

New Lows Spark Cannabis Science Inc (OTCMKTS:CBIS)

Cannabis Science Inc (OTCMKTS:CBIS) is back at the bottom of its trading range forming a new 52-week low of $0.0125. The stock touched $0.0127 in August before a significant spike to highs near $0.05. CBIS is one of the original pot stocks on the bb’s and has been at the forefront of this incredible phenomenon trading massive volume and rising to incredible highs.

When the sector heats up CBIS is the perfect vehicle; reasons for another sector surge include Canada’s new prime minister promising legalization immediately, DEA being told by California judge to stop interfering with dispensaries, billionaire Richard Branson suggesting a decriminalization amendment in the U.N. 6,000 non-violent drug offenders released Nov 1st, Australia lifting ban on medical mj, New York opening medical mj dispensaries January, Colorado revenues skyrocketing and more.

Cannabis Science Inc (OTCMKTS:CBIS) works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness.

CBIS initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Several years ago CBIS made a number of acquisitions in the cannabis sector that currently drive future growth. CBIS 2 most important drugs in development are:

The CS-S/BCC-1 drug program was launched in 2011 due to the “apparent success in 4 skin cancer patients who have self-administered cannabinoid based extracts topically to their skin cancers. These patients have experienced shrinking and apparent eradication of their skin cancer lesions.”

The drug CS-TATI-1 aims to target patients with drug-resistant HIV strains. The earliest article I could find relating to the launch of this program was in June 5, 2012, where the company loosely described a mission to “explore the commercial development of Phyto cannabinoid-based therapeutics for drug resistant HIV infection.”

To Find out the inside Scoop on CBIS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Looking at CBIS and all its vast and varied operating divisions, one might think they are a revenue generating power house but you would be very wrong; in fact CBIS has very limited operations, with minimal revenues to date and the Company continues to burn cash every quarter. This unfortunate situation has led to continued massive dilution with CBIS share count more than tripling over the past 3 years.

On January 14 CBIS announced it has received excellent feedback on its initial launch of its capsule products for sale in the California dispensary market.

CEO Raymond C. Dabney said “Our initial California test market has consumers giving us some amazing feedback to be combined with our proprietary information. We understand the value in using as much real consumer evidence in our drug development programs as possible. There are literally hundreds of dispensaries in the California market. We are ramping up our product offerings and now looking to expand on a very large scale. Following a bit more fine-tuning and test marketing, we will be launching our capsules and some other new products on a full-scale release across California; we are very excited and very motivated.’’

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $17 million market valuation CBIS has little assets or revenues and rising short term debt that has resulted in dilution over the years. But CBIS is an exciting story developing in small caps; the Company is specializing in the development of cannabis-based medicines and recently announced a Proposed NASDAQ Up Listing (that will never happen). CBIS is one of the original pot stocks with a long history of making spectacular 2000% plus moves that knows how to get its story into the national media so this is a great place to be when pot stocks heat up again. We will be updating on CBIS when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CBIS.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in CBIS either long or short and we have not been compensated for this article.

More articles

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.